Allogene Therapeutics, Inc.

https://www.allogene.com

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company dedicated to pioneering the development of genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. The company's mission is to lead the next revolution in cell therapy by delivering the first "off-the-shelf" allogeneic CAR T (AlloCAR T) products. Allogene Therapeutics is headquartered in South San Francisco, California.

Allogene is focused on developing a pipeline of "off-the-shelf" CAR T cell product candidates, which are derived from healthy donors for use in any patient, aiming to overcome the logistical and manufacturing limitations of patient-specific autologous therapies. Its key product candidates include cemacabtagene ansegedleucel (cema-cel) for Large B-Cell Lymphoma (LBCL), ALLO-316 for Renal Cell Carcinoma (RCC), and ALLO-329 for autoimmune diseases.

David Chang, M.D., Ph.D., serves as the President, CEO, and Co-Founder of Allogene Therapeutics. The company recently reported a positive interim futility analysis from its pivotal Phase 2 ALPHA3 trial for cema-cel in LBCL, demonstrating 58.3% MRD clearance. In April 2026, Allogene completed a public offering of common stock, raising $200.4 million, which is expected to extend its cash runway into the first quarter of 2028. Initial human translational data for ALLO-329 in autoimmune diseases are anticipated in June 2026. Allogene is positioned as a leader in the allogeneic CAR T therapy space, striving to provide more accessible and scalable cell therapy options.

Latest updates

Allogene Expands ALPHA3 Trial, Bolstered by Interim Data

Event summary

  • Allogene Therapeutics is expanding its pivotal Phase 2 ALPHA3 trial to South Korea and Australia, adding to existing sites in North America.
  • Regulatory clearance was received in both South Korea and Australia, with patient screening expected to begin in Q2 2026.
  • An interim futility analysis showed cema-cel achieved a 58.3% MRD clearance rate versus 16.7% in the standard-of-care arm.
  • The ALPHA3 trial aims to enroll approximately 220 patients by the end of 2027, with interim and primary analyses expected in mid-2027 and mid-2028 respectively.

The big picture

Allogene's expansion of the ALPHA3 trial represents a significant step in validating its AlloCAR T platform for first-line LBCL treatment, a market estimated to involve over 60,000 patients annually. The positive interim futility data provides early support for the MRD-guided approach, which aims to disrupt the standard 'watch and wait' protocol. However, the success of cema-cel hinges on demonstrating sustained efficacy and a manageable safety profile in the larger, global trial.

What we're watching

Clinical Efficacy
The full ALPHA3 trial data will be critical to assess whether the interim MRD clearance rates translate into meaningful improvements in event-free survival and overall patient outcomes, which will heavily influence the likelihood of BLA approval.
Enrollment Pace
The speed of patient enrollment in the expanded trial, particularly in South Korea and Australia, will indicate the level of investigator and patient buy-in and could impact the timeline for the primary analysis.
Regulatory Scrutiny
Given the increasing focus on cell therapy safety and efficacy, regulatory agencies will likely scrutinize the ALPHA3 trial data closely, potentially impacting the approval pathway for cema-cel.

Allogene Highlights Dual-Target CAR-T Approach at AACR

Event summary

  • Allogene presented preclinical data at AACR 2026 on dual CAR T cells targeting BCMA and CD70 for high-risk multiple myeloma.
  • CEO David Chang presented a symposium, 'Allogeneic CAR-T: Science at Scale,' outlining the company’s approach to allogeneic CAR T therapy.
  • Allogene’s R&D Chief Zachary Roberts participated in a forum discussing the evolving landscape of cell therapies.
  • The company is extending its Dagger® technology into autoimmune disease, applying its gene-edited, dual-targeting CAR T approach.

The big picture

Allogene’s focus on allogeneic CAR T therapy represents a strategic bet on simplifying cell therapy manufacturing and expanding patient access. While autologous CAR T therapies have demonstrated clinical efficacy, their complexity and cost have limited their reach. Allogene’s approach aims to overcome these limitations, but faces challenges in ensuring robust efficacy and managing potential immune responses against the allogeneic cells. The company's reliance on Cellectis for key technologies also introduces a degree of dependency.

What we're watching

Clinical Efficacy
The success of the BCMA/CD70 dual CAR T approach will hinge on demonstrating durable responses and manageable toxicity in clinical trials, particularly given the aggressive nature of high-risk multiple myeloma.
Manufacturing Scale
Allogene’s ability to transition from preclinical data to large-scale, consistent manufacturing of off-the-shelf CAR T products will be crucial for realizing its commercial ambitions and addressing patient demand.
Regulatory Pathway
The FDA’s acceptance of Allogene’s gene-editing approach for autoimmune disease, specifically the use of CRISPR technology, will set a precedent for similar therapies and influence the broader regulatory landscape.

Allogene Raises $200.4 Million in Stock Offering to Fuel Pipeline

Event summary

  • Allogene Therapeutics closed an underwritten public offering of 87.5 million shares at $2.00 per share.
  • The offering, including partial exercise of underwriters’ options, raised gross proceeds of $200.4 million.
  • Goldman Sachs, Jefferies, and TD Cowen served as joint bookrunners for the offering.
  • Proceeds are designated for general corporate purposes, including clinical trial, R&D, and administrative expenses.

The big picture

The $200.4 million raise provides Allogene with a crucial runway to continue developing its allogeneic CAR T therapies, a field facing challenges in scalability and manufacturing compared to autologous approaches. This offering underscores the ongoing need for biotech companies to access public markets for funding, particularly as R&D costs escalate. The low offering price ($2.00/share) suggests investor concern about the company’s valuation and execution risk.

What we're watching

Shareholder Dilution
The significant share issuance will dilute existing shareholders, and the market will scrutinize whether Allogene can generate sufficient returns to justify the increased share count.
Clinical Trial Progress
The company's ability to effectively deploy the raised capital into advancing its AlloCAR T pipeline through clinical trials will be a key determinant of future valuation.
Market Sentiment
Continued investor confidence in the broader cell therapy space, and specifically Allogene’s approach to off-the-shelf CAR T, will be crucial for maintaining its market position and accessing future capital.

Allogene's Dual-Targeted CAR-T Shows Promise in Autoimmune Pre-Clinical Data

Event summary

  • Allogene Therapeutics published pre-clinical data for ALLO-329, a dual-targeted CD19/CD70 CAR T therapy, in Nature Communications.
  • The data demonstrate ALLO-329's ability to eliminate B and T cells in systemic lupus erythematosus (SLE) models, halting autoantibody production.
  • A Phase 1 RESOLUTION trial is enrolling patients and expects initial data in June 2026, with a broader update planned for year-end.
  • ALLO-329 received three FDA Fast Track Designations for lupus, myositis, and scleroderma in April 2025.
  • The therapy utilizes Allogene's Dagger® technology to potentially reduce or eliminate the need for lymphodepletion.

The big picture

Allogene's ALLO-329 represents a significant effort to expand the application of CAR-T therapy beyond oncology into the large and underserved autoimmune disease market. The dual-targeting approach, combined with the Dagger® technology, aims to overcome key barriers to CAR-T adoption in autoimmune indications, such as the need for intensive lymphodepletion. Success here could unlock a multi-billion dollar market opportunity, but the clinical data will be crucial to validating the approach.

What we're watching

Clinical Efficacy
The June 2026 data release from the RESOLUTION trial will be critical in assessing whether ALLO-329's pre-clinical promise translates to meaningful clinical responses in patients with autoimmune diseases.
Lymphodepletion
The trial’s parallel cohorts, one with reduced lymphodepletion and one with none, will reveal whether ALLO-329 can achieve efficacy without the intensive pre-treatment, a key differentiator for broader adoption.
Competitive Landscape
The success of ALLO-329 will be weighed against competing CAR-T programs, many of which are pursuing higher cell doses, and will determine if Allogene's lower dose approach can establish a sustainable competitive advantage.

Allogene Raises $175 Million in Discounted Stock Offering

Event summary

  • Allogene Therapeutics priced an underwritten public offering of 87.5 million shares at $2.00 per share, raising gross proceeds of $175 million.
  • The offering includes a 30-day option for underwriters to purchase up to 13.125 million additional shares.
  • Proceeds will be used for general corporate purposes, including clinical trial expenses, R&D, and G&A.
  • The offering is expected to close on or about April 16, 2026.
  • Goldman Sachs, Jefferies, TD Cowen, Piper Sandler, William Blair, Baird, Canaccord Genuity, and TPG Capital BD are involved as underwriters.

The big picture

This capital raise underscores the ongoing challenges faced by clinical-stage biotech companies in accessing public markets, particularly those reliant on complex and expensive cell therapy programs. The discounted pricing signals a cooling investor sentiment towards the AlloCAR T space, potentially impacting the development timelines and funding strategies for other companies in the field. The $175 million injection provides Allogene runway, but the terms suggest a significant valuation reset.

What we're watching

Valuation Pressure
The $2.00 offering price represents a significant discount to Allogene's pre-announcement trading levels, suggesting investor concern about the company's near-term prospects and potentially impacting future financing options.
Clinical Trial Progress
The allocation of proceeds towards clinical trial expenses highlights the critical importance of upcoming data readouts; any setbacks or delays could trigger further downward pressure on the stock.
Underwriter Exercise
Whether the underwriters exercise their option to purchase the additional shares will be an indicator of their confidence in Allogene's future performance and the overall market appetite for the offering.

Allogene Therapeutics Seeks $175 Million in Public Offering

Event summary

  • Allogene Therapeutics announced a proposed public offering of $175 million in common stock.
  • The underwriters have a 30-day option to purchase an additional $26.25 million in shares.
  • Proceeds will be used for general corporate purposes, including clinical trial and R&D expenses.
  • The shelf registration statement was declared effective by the SEC on April 25, 2024.
  • Goldman Sachs, Jefferies, TD Cowen, and TPG Capital BD are acting as advisors for the offering.

The big picture

Allogene's move to raise $175 million underscores the continued need for capital in the cell therapy space, where development costs are substantial. The offering, utilizing a previously declared effective shelf registration, suggests a desire to capitalize on favorable market conditions. This capital injection will be crucial for Allogene to advance its AlloCAR T pipeline and compete with established players in the CAR-T market.

What we're watching

Market Reception
The success of this offering will hinge on investor sentiment towards allogeneic CAR-T therapies, given the competitive landscape and ongoing clinical trial results.
Capital Allocation
How effectively Allogene deploys the raised capital, particularly in advancing clinical trials and expanding its pipeline, will determine the long-term value creation.
Dilution Impact
The increased share count will dilute existing shareholders, and the market will scrutinize whether the capital raised justifies the resulting ownership dilution.

Allogene's LBCL Trial Data Bolsters AlloCAR-T Approach

Event summary

  • Allogene's ALPHA3 trial interim futility analysis showed 58.3% MRD clearance with cema-cel versus 16.7% in the observation arm in first-line consolidation LBCL.
  • The 41.6% absolute difference in MRD clearance exceeded a clinically meaningful benchmark of 25-30%.
  • Plasma ctDNA levels decreased by 97.7% in the cema-cel arm versus a 26.6% increase in the observation arm at Day 45.
  • The trial included community cancer centers, accounting for 33% of screening activity and infusions.
  • Enrollment is expected to complete by year-end 2027, with interim and primary EFS analyses anticipated in mid-2027 and mid-2028, respectively.

The big picture

The ALPHA3 trial data represents a significant step forward for allogeneic CAR-T therapy, which aims to address the limitations of autologous CAR-T by offering an 'off-the-shelf' solution. Success in LBCL, a challenging hematologic malignancy, could validate Allogene's platform and pave the way for broader applications in other cancers and autoimmune diseases. The trial's inclusion of community cancer centers highlights a strategic effort to expand access and potentially disrupt the existing CAR-T landscape, which has been largely concentrated in specialized academic centers.

What we're watching

Clinical Validation
Whether the observed MRD clearance rates in the interim analysis will translate to a statistically significant improvement in EFS and overall survival in the full trial results, which will be critical for regulatory approval.
Community Adoption
The pace at which community cancer centers integrate cema-cel into their treatment protocols will be a key indicator of Allogene's ability to achieve broad market penetration and scalability.
Competitive Landscape
How competing CAR-T therapies and emerging MRD-based treatment strategies will impact the potential market share and long-term commercial success of cema-cel.

Allogene's Pivotal LBCL Trial Futility Analysis Looms

Event summary

  • Allogene Therapeutics will announce the interim futility analysis results from its ALPHA3 Phase 2 trial on April 13, 2026.
  • The ALPHA3 trial is evaluating cemacabtagene ansegedleucel (cema-cel) as a first-line consolidation therapy for large B-cell lymphoma (LBCL).
  • The analysis will be presented during a conference call and webcast scheduled for 5:30 a.m. PT / 8:30 a.m. ET.
  • Allogene is developing allogeneic CAR T (AlloCAR T) therapies, aiming for 'off-the-shelf' availability.

The big picture

The ALPHA3 trial represents a critical inflection point for Allogene, as first-line consolidation is a high-value market segment in LBCL. Success here would validate Allogene’s allogeneic approach, which promises faster and more scalable therapy delivery compared to traditional autologous CAR-T. However, futility would raise serious questions about the efficacy of their platform and potentially trigger a reassessment of their broader pipeline strategy.

What we're watching

Clinical Efficacy
The futility analysis outcome will significantly influence the trial's continuation and the perceived viability of cema-cel in first-line LBCL, potentially impacting Allogene's valuation.
Manufacturing Scale
Success in LBCL will necessitate rapid scaling of Allogene's manufacturing processes to meet potential demand, a historically challenging aspect of CAR-T therapies.
Competitive Landscape
The ALPHA3 results will be closely scrutinized by competitors developing both autologous and allogeneic CAR-T therapies, potentially accelerating or decelerating their development timelines.

Allogene Data Milestone Signals Potential Shift in LBCL Treatment

Event summary

  • Allogene reported $258.3 million in cash and investments as of December 31, 2025, projecting runway into Q1 2028.
  • The pivotal Phase 2 ALPHA3 trial for cema-cel in first-line large B-cell lymphoma (LBCL) will have an interim futility analysis in April 2026.
  • Initial data from the Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease is expected in June 2026.
  • Allogene is exploring partnering opportunities for ALLO-316, currently in a Phase 1b cohort for renal cell carcinoma.

The big picture

Allogene's strategy hinges on demonstrating the efficacy and scalability of allogeneic CAR-T therapy, a potentially disruptive approach to cancer and autoimmune disease treatment. The ALPHA3 trial represents a high-risk, high-reward effort to redefine first-line LBCL treatment, while ALLO-329 aims to broaden the applicability of their Dagger® technology. The company's extended cash runway provides breathing room, but hinges on positive data readouts and potential partnerships to sustain operations.

What we're watching

Clinical Outcomes
The April 2026 interim futility analysis for ALPHA3 will be critical; failure to demonstrate meaningful MRD clearance could significantly impact the program's viability and Allogene's valuation.
Manufacturing Scale
Allogene's stated goal of delivering CAR-T at 'biologic-like scale' requires demonstrating efficient and cost-effective manufacturing processes, a persistent challenge for allogeneic therapies.
Autoimmune Expansion
The success of the ALLO-329 RESOLUTION trial, particularly the ability to reduce or eliminate lymphodepletion, will determine whether Allogene can meaningfully expand into the autoimmune disease market, a significantly larger addressable space than oncology.

Allogene Set to Detail 2025 Results Amidst CAR-T Therapy Scaling Challenges

Event summary

  • Allogene Therapeutics will report Q4 and full-year 2025 financial results on March 12, 2026, after market close.
  • A live webcast and conference call will follow the announcement at 2:00 p.m. PT / 5:00 p.m. ET.
  • The company is developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease.
  • Allogene's technology aims to deliver 'off-the-shelf' CAR T cell therapy on-demand at scale.

The big picture

Allogene's focus on allogeneic CAR-T therapy represents an attempt to overcome the limitations of current autologous CAR-T approaches, which are costly and complex. The company’s success hinges on its ability to scale production and demonstrate clinical efficacy, a challenge facing the broader cell therapy sector. The upcoming results will be a key indicator of whether Allogene can translate its technology into a commercially viable platform.

What we're watching

Execution Risk
The company's stated goal of delivering readily available, on-demand CAR T therapy faces significant manufacturing and logistical hurdles, and the results will reveal the progress made toward that ambitious goal.
Regulatory Headwinds
Given the novelty of the technology, regulatory approval timelines and potential requirements remain uncertain, and the update will likely shed light on any interactions with regulatory bodies.
Financial Sustainability
Clinical-stage biotechnology companies often rely on continued funding; the reported financials will indicate the company's burn rate and its ability to secure further investment to support its pipeline.

Allogene Sets 2026 as Key Test for Scalable CAR-T Platform

Event summary

  • Allogene Therapeutics has designated 2026 as a pivotal year for its allogeneic CAR-T platform, anticipating key clinical readouts in both oncology and autoimmune disease.
  • An interim futility analysis for the ALPHA3 trial (cema-cel in LBCL) is planned for early Q2 2026, assessing MRD clearance.
  • Initial proof-of-concept data for ALLO-329, a dual CD19/CD70 AlloCAR T utilizing Dagger® technology, is expected by the end of 1H 2026.
  • The company projects cash runway extending into 2H 2027.
  • Allogene has treated over 200 patients across six clinical studies, building a platform targeting scalable economics (<$10K - $20K/dose).

The big picture

Allogene's strategy hinges on proving the viability of 'off-the-shelf' CAR-T therapy, a model that promises to overcome the limitations of current personalized approaches. The company's focus on scalability and accessibility represents a direct challenge to the bespoke, high-cost nature of existing cell therapies, but success requires demonstrating clinical efficacy and operational efficiency at a large scale. The 2026 milestones are a crucial inflection point for validating this ambitious vision.

What we're watching

Clinical Efficacy
The ALPHA3 trial's futility analysis will be critical; a failure to demonstrate meaningful MRD clearance could significantly impact investor confidence and future development plans for cema-cel.
Manufacturing Scale
Allogene's ability to achieve its projected manufacturing scalability (30,000-60,000+ doses annually) and cost-of-goods targets will be essential for realizing the platform's commercial potential.
Autoimmune Expansion
The RESOLUTION trial's initial data for ALLO-329 will reveal whether the Dagger® technology can effectively reduce lymphodepletion and broaden access in autoimmune disease, a significantly larger market than oncology.
CID: 536